Premium
Immunotherapy of ovarian carcinoma. An experimental model
Author(s) -
Order Stanley E.,
Donahue Valentina,
Knapp Robert
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197309)32:3<573::aid-cncr2820320309>3.0.co;2-4
Subject(s) - antiserum , medicine , heterologous , transplantation , immunotherapy , antibody , serology , antigen , ovarian carcinoma , carcinoma , immunofluorescence , ovarian cancer , immunology , pathology , cancer , biology , biochemistry , gene
The specificity of a tumor antigen of an experimental ovarian carcinoma was determined by immunofluorescence, cytotoxicity, and immunoelectro‐phoresis using an absorbed heterologous tumor antiserum. Tumor controls and normal rabbit sera controls were compared to tumor antiserum‐treated recipients. Tumor control animals died by the 36th day after tumor transplantation. Normal rabbit serum was shown to contain a natural antibody which prolonged survival. Treatment with unabsorbed tumor antiserum in vitro led to 100% survival; 24 hours after tumor transplantation 30–40% survival; 48 hours after tumor transplantation 50%; and when animals with advanced disease were treated from the 4th‐8th day with daily injections this resulted in 30% long‐term survivors. The intraperitoneal administration of tumor antiserum allows for direct binding with tumor cells without dilution in the circulation and at a reduced risk of nonspecific binding in critical organs and demonstrates the efficacy of serologic immunotherapy.